Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zalifrelimab + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Agenus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Zalifrelimab (AGEN1884) is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), acting as an immune checkpoint inhibitor to enhance the immune system's ability to recognize and destroy cancer cells. Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), also functioning as an immune checkpoint inhibitor by blocking the PD-1 pathway and preventing cancer cells from evading immune detection. The combination of zalifrelimab and pembrolizumab is being investigated in clinical trials for advanced solid tumors and metastatic non-small cell lung cancer (NSCLC). This combination aims to provide synergistic activation of the immune response against tumors by inhibiting two distinct checkpoints—CTLA-4 and PD-1[3][5][6].
- Brand names
- Keytruda
- Other names
- AGEN1884AGEN-1884AGEN 1884zalifrelimabpembrolizumabKeytruda
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on zalifrelimab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zalifrelimab + pembrolizumab.